BTIG Research Reiterates Hold Rating for Abbott Laboratories (ABT)

BTIG Research restated their hold rating on shares of Abbott Laboratories (NYSE:ABT) in a report issued on Sunday.

A number of other equities analysts have also recently weighed in on the stock. Zacks Investment Research upgraded shares of Abbott Laboratories from a hold rating to a buy rating and set a $67.00 price objective for the company in a research report on Friday, April 20th. ValuEngine upgraded shares of Abbott Laboratories from a hold rating to a buy rating in a research report on Thursday, March 1st. Argus upped their price objective on shares of Abbott Laboratories from $66.00 to $80.00 and gave the stock a buy rating in a research report on Tuesday, January 30th. They noted that the move was a valuation call. Citigroup upped their price objective on shares of Abbott Laboratories from $59.00 to $64.00 and gave the stock a neutral rating in a research report on Tuesday, January 30th. Finally, Barclays upped their price objective on shares of Abbott Laboratories from $66.00 to $70.00 and gave the stock an overweight rating in a research report on Thursday, January 25th. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. The company presently has an average rating of Buy and an average target price of $67.06.

Shares of NYSE ABT opened at $58.65 on Friday. Abbott Laboratories has a 1 year low of $42.88 and a 1 year high of $64.60. The firm has a market cap of $102,754.29, a P/E ratio of 23.46, a PEG ratio of 1.71 and a beta of 1.50. The company has a current ratio of 2.26, a quick ratio of 1.86 and a debt-to-equity ratio of 0.87.



Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Wednesday, April 18th. The healthcare product maker reported $0.59 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.58 by $0.01. Abbott Laboratories had a net margin of 1.67% and a return on equity of 14.53%. The firm had revenue of $7.39 billion for the quarter, compared to the consensus estimate of $7.28 billion. During the same period in the prior year, the firm posted $0.48 earnings per share. The firm’s quarterly revenue was up 16.7% compared to the same quarter last year. research analysts anticipate that Abbott Laboratories will post 2.86 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, May 15th. Stockholders of record on Friday, April 13th will be given a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a dividend yield of 1.91%. The ex-dividend date of this dividend is Thursday, April 12th. Abbott Laboratories’s dividend payout ratio (DPR) is 44.80%.

In other news, insider Jaime Contreras sold 849 shares of the stock in a transaction dated Monday, April 23rd. The shares were sold at an average price of $59.36, for a total value of $50,396.64. Following the completion of the sale, the insider now directly owns 50,436 shares in the company, valued at $2,993,880.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Brian J. Blaser sold 27,733 shares of the stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $62.26, for a total transaction of $1,726,656.58. Following the completion of the sale, the insider now owns 156,587 shares of the company’s stock, valued at $9,749,106.62. The disclosure for this sale can be found here. Insiders sold 125,110 shares of company stock valued at $7,610,384 over the last quarter. Company insiders own 0.74% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the company. IFG Advisory LLC acquired a new stake in Abbott Laboratories during the fourth quarter worth about $2,824,000. Rowland & Co. Investment Counsel ADV acquired a new stake in Abbott Laboratories during the fourth quarter worth about $102,000. Icon Wealth Partners LLC acquired a new stake in Abbott Laboratories during the fourth quarter worth about $102,000. SWS Partners acquired a new stake in Abbott Laboratories during the fourth quarter worth about $104,000. Finally, Cerebellum GP LLC acquired a new stake in Abbott Laboratories during the fourth quarter worth about $133,000. Institutional investors and hedge funds own 72.32% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This report was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this report on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this report can be accessed at https://stocknewstimes.com/2018/04/26/btig-research-reiterates-hold-rating-for-abbott-laboratories-abt.html.

Abbott Laboratories Company Profile

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon.

Analyst Recommendations for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply